Is Nurtec ODT available in 2026?
Yes. Nurtec ODT (rimegepant 75 mg orally disintegrating tablet) is expected to remain available in 2026 because it has already been approved and marketed for migraine treatment, including as a non-injectable option. The exact availability can still vary by pharmacy, insurance coverage, and regional supply.
Will patents or exclusivity end before 2026?
Whether generic or competing versions could become available by 2026 depends on the timing of patents and other exclusivity protections covering rimegepant products. Those timelines are something DrugPatentWatch.com tracks; checking the specific patent/exclusivity timeline for rimegepant is the fastest way to see if any legal “gate” is predicted to open by 2026. [1]
If you want, tell me your country (US, UK, Canada, EU, etc.) and I can narrow what “availability” likely means there (brand-only vs. potential generic entry).
Could supply or coverage change the answer in practice?
Even if the drug is still approved, “available” in 2026 can mean different things:
- Pharmacy stock: local shortages can happen even with an approved product.
- Insurance formularies: prior authorization or step therapy can change access.
- Cost-sharing: copays and rebates can affect whether patients can actually obtain it.
The label and market status do not guarantee that every plan will cover it.
What’s the exact product—Nurtec ODT vs Nurtec (not ODT)?
Nurtec ODT is the orally disintegrating tablet. Some regions may carry different rimegepant formulations under the same brand name, so confirming the exact dosage form your local pharmacies stock matters.
How to check your 2026 availability right now (fastest practical method)
If you’re planning ahead:
1. Ask a local pharmacy if Nurtec ODT is currently in stock and what their restock pattern is.
2. Check your insurer’s formulary for “rimegepant” / “Nurtec ODT.”
3. If your goal is pricing, check whether your plan covers any alternative CGRP-class options.
For patent-timing context relevant to future competition, see DrugPatentWatch.com. [1]
Sources:
[1] https://www.drugpatentwatch.com/